

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

( 深圳市海普瑞藥業集團股份有限公司 )

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

### INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Shenzhen Heparin Pharmaceutical Group Co., Ltd. (the **Company**), together with its subsidiary, the **Group**). Pursuant to the Inside Information Provisions of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (**Listing Rules**).

The board of directors (the **Directors**) of the Company (the **Board**) is informed that the shareholders of the Company (the **Shareholders**) and special interest holders of Techdow Pharma Italia S.R.L., a wholly owned subsidiary of the Company (the **Techdow Italy**), informed the Board of a confidential acquisition of a 11.7% stake in the Company (the **Incident**). The Company has filed a confidential acquisition report with the relevant authorities. The Board has decided to file a confidential acquisition report with the relevant authorities. The Board has decided to file a confidential acquisition report with the relevant authorities.

The Board of the Company has decided to file a confidential acquisition report with the relevant authorities. The Board has decided to file a confidential acquisition report with the relevant authorities. The Board has decided to file a confidential acquisition report with the relevant authorities.

The independent members of the Board have held the Techdial, handle the I side. After the investigation of the I side, the company will cease to be a special dividend. The Board has decided 31 December 2023 (FY2023).

The Board is investigating the I side, the general and will cease to be a special dividend. The Board has decided 31 December 2023 (FY2023).

The Board has held the general meeting of the Company and decided to appoint Li Li as the Chairman of the Board.

The Board will take the necessary measures to keep the Shareholders and the independent members of the Board informed of the investigation of the I side and the general meeting. The Board has decided to appoint Li Li as the Chairman of the Board for FY2023 (Annual Results), which is expected to be published in March 2024. The independent members of the Board, and the special dividend will be issued to the Shareholders.

**Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
January 15, 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.*